15.11.2020 – CORAT Therapeutics CEO Dr. Andreas Herrmann today proudly reports the conclusion of the production campaign providing the first larger batch of COR-101 ready for the patients. COR-101 is a fully human antibody developed in Braunschweig which efficiently blocks the cell entry of the SARS-CoV-2, thereby preventing infection with the Coronavirus.
Because COR-101 directly attacks the virus, its clinical use will focus on helping the patients who cannot be cured by vaccination as this is the most urgent medical need in the pandemic. However, it is expected that it will also protect the uninfected, which will be tested in a second step.
Human antibodies are molecules produced by our own body to fight infections. COR-101 is one of these antibodies. It can be made in large quantities by biotechnological manufacturing, to immediately help to neutralize the coronavirus in those patients who cannot built enough of their own antibodies in time.
„We are extremely happy and would like to thank everybody who helped to make this happen so quickly. With acute case numbers rising fast, CORAT hopes to make a difference by providing an option soon to directly treat the Coronavirus-Infected. We hope that the clinical studies now can commence very soon.“
Dr. Andreas Herrmann, CEO of CORAT Therapeutics.
